Vaxcyte (PCVX) is a publicly traded Healthcare sector company. As of May 20, 2026, PCVX trades at $47.17 with a market cap of $6.99B and a P/E ratio of -12.31. PCVX moved -3.28% today. Year to date, PCVX is +2.48%; over the trailing twelve months it is +28.99%. Its 52-week range spans $27.66 to $118.62. Analyst consensus is strong buy with an average price target of $109.43. Rallies surfaces PCVX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies organizes PCVX SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
| Metric | Value |
|---|---|
| Price | $47.17 |
| Market Cap | $6.99B |
| P/E Ratio | -12.31 |
| EPS | $-3.80 |
| Dividend Yield | 0.00% |
| 52-Week High | $118.62 |
| 52-Week Low | $27.66 |
| Volume | 3.93M |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-463.93M |
| Gross Margin | 0.00% |
8 analysts cover PCVX: 0 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $109.43.